Hormone replacement therapy prevents failure after total knee (TKA) and hip (THA) arthroplasty: a population-based retrospective cohort study  by Prieto-Alhambra, D. et al.
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S176Conclusions: This open-label study shows that i.a. HA injection for TMCJ
OA leads to a signiﬁcant improvement in all the investigated parameters,
which is still present after six months from baseline. There are currently
two broad categories proposed for the mechanism of action by which HA
may elicit short-and long-term pain relief: rheological or biomechanical
and biological (anti-inﬂammatory, anabolic, analgesic, chondroprotective
and anticatabolic) effects through interactions between HA and its
receptors CD44, RHAMM, ICAM-1. It is possible that one of the functions of
CD44 in stem cells may be to facilitate the endocytosis of HA which then
may act as a protector of their DNA from oxidants. Our study conﬁrms that
i.a. injections of HA in TMCJ are easily administered, and may give symp-
tomatic beneﬁt with minimal side effects.
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CHRONIC EFFECTS OF A FLEXIBLE AND MINIMALIST FOOTWEAR ON
CLINICAL, FUNCTIONAL AND GAIT BIOMECHANICAL ASPECTS IN THE
KNEE OSTEOARTHRITIS: A SINGLE-BLIND RANDOMIZED CLINICAL
TRIAL
F. Trombini-Souza, A. Matias, M. Yokota, C. Schainberg, R. Fuller,
I.C. Sacco. Univ. of Sao Paulo, Sao Paulo, Brazil
Purpose: Recent studies have shown that the acute use of shoes that
mimic barefoot gait decrease substantially knee loads while walking in
elderly with knee osteoarthritis (OA). Probably due to methodological
difﬁculties to implement this type of conservative treatment during
extended period, the effectiveness of minimalist footwear has not been
evaluated yet in elderly patients with knee OA. The purpose is to describe
a randomized clinical trial protocol for evaluating the therapeutic effect of
a minimalist (ﬂexible, non-heeled) and inexpensive footwear on clinical,
functional, and biomechanical gait in elderly women with knee OA.
Methods: Fifty six elderly womenwith knee OA grade 2 or 3 (Kellgren and
Lawrence) will be randomized in blocks and allocated in the intervention
group thatwill use aﬂexiblenon-heeled shoes -Moleca for at least 6hours
daily or in the control group, which could not use these shoes or be under
physical therapy or acupuncture treatment throughout these sis months.
The use of Paracetamol 500mg every six hour was allowed for both groups
in case of pain.Moleca (CalçadosBeiraRio S.A., NovoHamburgo, RS, Brazil)
is a women's double canvas ﬂexible ﬂat walking shoe without heels, with
a 5-mm anti-slip rubber sole and a 3-mm internal wedge of ethylene vinyl
acetate. The mean weight is 17219.6 g, ranging from 142 to 193 g
depending on the size. Both groups will be followed during 6months. They
will be assessed at baseline condition, after 3 months (intervention group)
and after 6months of baseline condition (end of intervention, both groups).
All the assessments will be performed by a physiotherapist that is blind to
which group the patientwas allocated. Themain outcome assessment is the
pain WOMAC score and the secondary outcomes are other WOMAC scores
pain assessment (visual analogue scale - VAS), Lequesne index, Six-Minute
Walk Test, and biomechanical gait analysis by means of 6 infrared cameras
and a multi-component force plate to determine the knee adduction
moment during gait. At baseline, all patients receive a diary to record the
hours of daily use of footwear intervention. Every two weeks, the same
physiotherapist carries phone calls to all patients in order to verify adher-
ence to treatment and the correctﬁlling this diary. The intergroupand inter-
moments will be performed by repeated measures analysis of variance
(a¼0.05). This Trial was approved by the local Ethics Committee and was
registered in ClinicalTrials.gov Identiﬁer: NCT01342458.
Results: Six hundred thirty-four elderly women have been contacted so far
and 20 have already been allocated in the intervention group (9) and in the
control (11). Five patients from intervention group have already completed
all 3 assessments and ﬁnished the protocol. The preliminary results have
shown that the elderly women of the intervention group have used the
Moleca shoe for an average monthly of 7 hours and 24 minutes ( 3:47),
corresponding to approximately 50% of the home-work hours of the day.
Conclusion: This is the ﬁrst randomized clinical trial protocol to assess the
chronic effect of a minimalist footwear on the clinical, functional and gait
biomechanics of elderly women with knee osteoarthritis. We expect that
the use of Moleca shoes for 6 months provides pain relief, reduction of
the knee adduction moment while walking and improves joint function in
elderly women with knee OA, and therefore can be considered as another
inexpensive option for conservative OA treatment.The authors are pleased to acknowledge the ﬁnancial support of State of
São Paulo Research Foundation - FAPESP (processes: 2011/01640-8, 2011/
03300-0, 2011/03069-6).
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RANDOMIZED, DOUBLE-BLIND CONTROL TRIAL OF PERI-ARTICULAR
HYALURONIC ACID:BOTULINUS TOXIN INJECTION IN LATERAL
EPICONDYLOSIS.
R.J. Petrella 1,2, J. Decaria 1, M. Petrella 1. 1U Western Ontario, London, ON,
Canada; 2 Lawson Hlth.Res. Inst., London, ON, Canada
Purpose: To compare and describe the effects of peri-articular hyaluronic
acid (HA) coadminsitered with botulinus toxin (Botox) versus placebo in
lateral epicondylosis.
Methods: 28 patients with elbow pain longer than two weeks and less
than 12 months, particularly exacerbated during resisted dorsiﬂexion of
thewrist with the elbow in full extensionwith a VAS score> 4.5 cm on a 0-
10 cm VAS were included. Assessments were done at baseline, days 7, 14,
30 and 90. Efﬁcacymeasures included patient's visual analogue scale (VAS)
of pain at rest (0-100 mm) and following assessment of grip strength (0-
100 mm). Grip strength was determined using a jamar hydraulic hand
dynamometer. Other assessments included patients’ global assessment of
elbow injury (5 point categorical scale; 1 ¼ no disability, 5 ¼ maximal
disability), patients’ assessment of normal function/activity (5 point
categorical scale), patients/physician satisfaction assessment (10 point
categorical scale), and adverse events as per WHO deﬁnition. Differences
between groups were determined using an intent-to-treat ANOVA. After
outcome assessment, patients were randomized to treatment with a single
injection of: HA + Botox (0.7 cc HA + 40 units Botox), HA alone (0.7 cc),
Botox (40 units), placebo (normal saline 0.7 cc). Injections were done free-
hand into the origin of the extensor carpi radialis brevis (ECRB).
Results: All patients completed the trial. Adverse events included pain and
swelling in one patient in the HA group at day 7 and ECRB weakness for 48
hours in one patient in the Botox group following injection. At 7 days,
a signiﬁcant improvement (p<0.05) from baseline and versus placebo in
VAS pain at rest and following grip testing was observed in all three
treatment groups. Grip strength was greater (p<0.05) for HA+Botox vs
other groups at 14, 30 and 90 days. Further, HA +Botox showed small but
signiﬁcant patient perception of normal function versus HA or Botox at one
month (p<0.05). However, at 90 days, HA+ Botox showed signiﬁcantly
(p<0.03) greater physician satisfaction versus all other groups. There were
no differences in patient global satisfaction between treatment groups at 7
or 90 days, but HA + Botox showed greater satisfaction at 14 and 30 days.
Conclusion: Peri-articular HA + Botox produced superior clinical and
statistical improvement in short- and long-term pain and function
compared to placebo and Ha or Botox alone with serious adverse effects.Epidemiology & Health Services Research
349
HORMONE REPLACEMENT THERAPY PREVENTS FAILURE AFTER TOTAL
KNEE (TKA) AND HIP (THA) ARTHROPLASTY: A POPULATION-BASED
RETROSPECTIVE COHORT STUDY.
D. Prieto-Alhambra 1,2, M. Javaid 1, A. Judge 1, J. Maskell 3, C. Cooper 1,3,
N.K. Arden 1. 1Botnar Res. Ctr., Univ. of Oxford, Oxford, United Kingdom;
2 Inst. Català de la Salut-IDIAP Jordi Gol, Barcelona, Spain; 3MRC Lifecourse
Epidemiology; Southampton Univ., Southampton, United Kingdom
Purpose: Rates of primary total knee (TKA) and hip (THA) arthroplasties
are increasing worldwide. Together with patient reported outcomes,
implant survival is an important element in the evaluation of joint
replacement surgery. There is an urgent need to identify potential inter-
ventions to improve implant outcomes. Hormone replacement therapy
(HRT) might minimise osteolysis and loosening through its anti-resorptive
effects, and hence improve prosthesis survival.
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S177Therefore, we assessed whether HRT use is associated with reduced
implant failure rates in a community-based cohort.
Methods: Study population: Female participants in the General Practice
Research Database undergoing a TKA or THA from 1986 to 2006 were
included. Revision surgery was identiﬁed using READ codes. In order to
identify arthroplasties indicated for osteoarthritis, we excluded patients
aged <40 years at the date of surgery, and those with a history of either
previous hip fracture or rheumatoid arthritis.
Exposure: Women with at least 6 prescriptions of HRT or 6 months on
therapy with a high (>80%) adherence were identiﬁed as HRT users. Three
sensitivity analyses were carried out, where we explored the association
between HRT use for12 months, HRT adherence and cumulative use, and
time to failure. We used time varying Cox Models to account for the
immortal time till met deﬁnition of HRT use.
Statistical analysis: Time-varying Cox models were used to estimate hazard
ratios (HR) for HRT users versus non-users matched by propensity score to
minimize for confounding by indication. Potential confounders were: age,
gender, body mass index, joint replaced (hip/knee), year of surgery, OA
indication, fracture history, anti-osteoporosis medication use, oral gluco-
corticoids, smoking, alcohol intake, multiple deprivation index, UK region,
co-morbid conditions, and use of drugs which can affect bone metabolism.
Results: Of 24,733 eligible women included, 3,644 met the deﬁnition of
HRT user and the remaining 21,089 were non-users. From the propensity-
matching, 2,700 HRT users and 3 comparable controls (8,100women)were
selected. The median (interquartile range) follow-up was 3.3 (1.5-6.1)
years after surgery. Despite matching, HRT users were more likely to be
taking drugs with increase fracture risk.
A total of 168 (1.56%) participants underwent revision surgery during the
period of followup. The cumulative failure rate was signiﬁcantly lower in
HRT users than non-users (27(1.00%) vs 141(1.74%, p¼0.007)). HRT use for
6 months was associated with a lower risk of revision (HR 0.61 (0.41 to
0.93)) [Figure]. Both higher adherence (p¼0.007) and longer therapy
duration (p¼0.008) led to further reductions in revision rates. [Table].Sensitivity analyses: effect of adherence and cumulative use of HRT on implant surv
Exposure N (%)
HRT MPR Non-user 8,100 (75.0%)
< 0.4 1,631 (15.1%)
0.4 to < 0.8 594 (5.5%)
 0.8 475 (4.4%)
p for trend
HRT Cumulative use (DDD) Non-user 8,100 (75.0%)
<365 507 (4.7%)
365 to 1,065 1,180 (10.9%)
>1,065 1,013 (9.4%)
p for trend
ĂConclusions: HRT use for at least 6 months is associated with an up to 40%
reduction in prosthesis failure after lower limb total joint arthroplasty.
Hormone therapy for at least 1 year appeared related to further reduction
in failure rates to about 50%. This supports evidence that there is a signif-
icant protective beneﬁt of anti-resorptive drugs in patients undergoing
lower limb arthroplasty. These ﬁndings require replication in formal
randomized controlled trials.
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LATENT CLASS CLUSTER ANALYSIS SHOWS FOUR DISTINCT SUBTYPES
OF KNEE OA: DATA FROM THE OSTEOARTHRITIS INITIATIVE.
J.H. Waarsing, S.M. Bierma-Zeinstra, H. Weinans. Erasmus MC, Rotterdam,
Netherlands
Purpose: A possible explanation for the seeming complexity of osteoar-
thritis is that it is not one disease, but a collection of disease sub-types with
different aetiology and clinical characteristics. In this study we used latent
class cluster analysis to ﬁnd subtypes of knee osteoarthritis based on OA
characteristics in the baseline data of the Osteoarthritis Initiative (OAI).
Methods: Latent class cluster analysis (LCA) is a model based clustering
approach that assumes the existence of a latent variable (the various
clusters) that inﬂuences a set of observed variables, in this case OA char-
acteristics. The optimal number of clusters was determined based on the
BIC (Bayesian Information Criterion) that informs on the goodness of ﬁt of
the model, and the AWE (ApproximateWeight of Evidence) which informs
on the ability to classify subjects into the various clusters.
The OA characteristics that served as input for the LCA was formed by the
set of x-ray scores of different features, quantitative MRI cartilage
measures and various clinical scores like WOMAC and VAS from 520
subjects of the OAI progression cohort at baseline.
Since OA increases in severity over time, a cluster analysis can only be
meaningful when performed independent of disease severity. To accom-
plish this we included a severity variable into the model, such that a model
ﬁt was obtained adjusted for severity. The severity variable was obtained
by performing Latent Class Factor analysis, which is similar to principle
component analysis, but works for both continuous and categorical data.
The same set of OA characteristics was used as input.
Results:Ourmethod resulted in 4 clusters, of which the 1st contained 47% of
the subjects, the2nd27%, the 3rd15%and the4th12%of the subjects. Clusters
1, 2 and 4 showed mainly medial cartilage degeneration, while cartilage
degeneration in the 3rd clusteroccurred laterally. Interestingly, clusters 3 and
4 showed a strong increase in area of denuded bone with increasing OA
severityasmeasuredonMRI,while cluster 1 did not showanydenudedbone,
independentofOAseverity. Cluster2 showedaverymild increase indenuded
bone areawith increasing OA severity. Pain scores increased with increasing
severity in all clusters. Pain scores were lower in the 3rd cluster, signiﬁcantly
so in the VAS scores reﬂecting pain in the last month (p<0.05).
We further examined if there were difference in the presence of risk-
factors between the clusters. There were no differences in the presence of
heberden's nodes or BMI. However, clusters varied with respect to repor-
ted trauma. Prevalence of traumawas lowest in cluster 1 (33%) and highest
in cluster 4 (56%).
Finally, using the x-ray scores at 48 months, we looked at differences in
progression, characterized by the prevalence of subjects that increased inival
Failure incidence (/1,000 py) [95%CI] HR [95%CI]; p-val
4.25 [3.61 to 5.02] REFERENCE
3.04 [1.94 to 4.76] 0.70 [0.44 to 1.14]; p¼0.15
2.98 [1.34 to 6.63] 0.66 [0.29 to 1.50]; p¼0.33
0.97 [0.24 to 3.86] 0.22 [0.05 to 0.89]; p¼0.033
0.007
4.25 [3.61 to 5.02] REFERENCE
5.24 [2.73 to 10.07] 1.23 [0.63 to 2.42]; p¼0.54
1.74 [0.83 to 3.65] 0.40 [0.19 to 0.86]; p¼0.019
2.39 [1.33 to 4.32] 0.53 [0.29 to 0.99]; p¼0.046
0.008
